药物治疗对比安慰剂或常规治疗用于心脏骤停后昏迷幸存者:系统评价与Meta分析
该系统评价检索截至2024年10月20日,纳入45项RCT共5800例心脏骤停后昏迷幸存者,评估30种药物对比安慰剂或常规治疗对预后的影响,主要终点为30天/出院时死亡率。仅4项研究报告降低死亡率:1项抗胆碱能药戊乙奎醚、2项心脏骤停期间使用血管加压素联合甲泼尼龙及复苏后休克加氢化可的松、1项中药参附。类固醇(n=739,RR 0.93,95%CI 0.83-1.04,p=0.21,I²=60%,低确定性)、辅酶Q10(n=107,RR 0.91,95%CI 0.61-1.37,p=0.65,I²=0%,低确定性)、硫胺素(n=149,RR 1.11,95%CI 0.88-1.40,p=0.39,I²=0%,极低确定性)的Meta分析均未检出对死亡率的影响。作者认为多数药物试验未报告对死亡率的影响,低确定性证据提示需进一步研究。
要点
- 45项RCT共5800例心脏骤停后昏迷幸存者,30种药物中仅4项研究报告降低30天/出院死亡率。
- 类固醇Meta分析(n=739)对死亡率无效应:RR 0.93,95%CI 0.83-1.04,p=0.21,I²=60%,证据确定性低。
- 辅酶Q10(n=107)RR 0.91,95%CI 0.61-1.37,p=0.65,I²=0%,证据确定性低。
- 硫胺素(n=149)RR 1.11,95%CI 0.88-1.40,p=0.39,I²=0%,证据确定性极低。
- 报告降低死亡率的4项研究分别涉及戊乙奎醚、心脏骤停期间血管加压素联合甲泼尼龙及复苏后休克加氢化可的松(2项)、中药参附。
适用人群与场景
- 心脏骤停后昏迷幸存者,纳入重症监护治疗场景。
研究设计与关键结果
- 系统评价与Meta分析:检索Medline、EMBASE、Cochrane Central Register of Controlled Trials及The International Clinical Trials Registry Platform,最后检索日期2024年10月20日。
- 从2562条记录中筛选207篇全文,最终纳入45项研究共5800例患者,涉及30种治疗。
- 研究按主题分组:支持性药物治疗(n=10)、神经保护剂(n=19)、抗炎/抗氧化剂(n=16)。
- 4项研究报告降低30天/出院死亡率:1项抗胆碱能药戊乙奎醚;2项心脏骤停期间使用血管加压素联合甲泼尼龙及复苏后休克加氢化可的松;1项中药参附。
- 类固醇Meta分析(n=739):RR 0.93,95%CI 0.83-1.04,p=0.21,I²=60%,证据确定性低。
- 辅酶Q10 Meta分析(n=107):RR 0.91,95%CI 0.61-1.37,p=0.65,I²=0%,证据确定性低。
- 硫胺素Meta分析(n=149):RR 1.11,95%CI 0.88-1.40,p=0.39,I²=0%,证据确定性极低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入随机对照试验。
- 偏倚风险评估采用Cochrane Risk-Of-Bias Version 1。
- 主要结局为30天/出院时死亡率,其他结局参照心脏骤停核心结局集(Core Outcome Set for Cardiac Arrest)。
- 局限性:作者指出证据确定性低,需进一步研究。
对床旁实践的改变
- 作者认为,多数心脏骤停后昏迷幸存者的药物治疗试验未报告对死亡率的影响,类固醇、辅酶Q10和硫胺素的Meta分析未显示对死亡率有获益证据,但证据确定性低,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In Europe, approximately 291,000 cardiac arrests occur annually. Despite critical care therapy, hospital mortality remains high. This systematic review assessed whether, in comatose survivors of cardiac arrest, any drug therapy, compared to placebo or usual care, improves outcomes.
METHODS: We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, and The International Clinical Trials Registry Platform for randomized controlled trials of drug therapy in comatose survivors of cardiac arrest (last searched 20th October 2024). The primary outcome was mortality at 30 days/hospital discharge. Other outcomes reflected those of the Core Outcome Set for Cardiac Arrest. Risk of bias was assessed using Cochrane Risk-Of-Bias Version 1. Studies of steroids, coenzyme Q10 and thiamine were meta-analysed.
RESULTS: From 2562 records, 207 full texts were screened and 45 studies (5800 patients) investigating 30 therapies were included. Studies were grouped thematically as supportive drug therapies (n = 10), neuroprotective agents (n = 19), and anti-inflammatory/antioxidants (n = 16). Four studies reported reduced mortality at 30 days/hospital discharge: one of the anticholinergic penehyclidine hydrochloride, two of intra-arrest vasopressin and methylprednisolone plus hydrocortisone for post resuscitation shock, and one of the traditional Chinese medicine, shenfu. Studies of steroids, coenzyme Q10 and thiamine were meta-analysed. We could not detect an effect on mortality with steroids (n = 739, risk ratio (RR), 0.93; 95 % CI 0.83-1.04, p = 0.21; I2 = 60 %, low certainty), coenzyme Q10 (n = 107, RR, 0.91; 95 % CI 0.61-1.37, p = 0.65; I2 = 0 %, low certainty), or thiamine (n = 149, RR, 1.11; 95 % CI 0.88-1.40, p = 0.39; I2 = 0 %, very low certainty).
CONCLUSION: In comatose survivors of cardiac arrest, the majority of trials of drug therapy reported no effect on mortality. Meta-analyses of steroids, coenzyme Q10 and thiamine demonstrated no evidence of an effect on mortality. However, the low certainty of evidence warrants further research.
参考来源
- McGuigan PJ, Pauley E, Eastwood G, et al. Drug therapy versus placebo or usual care for comatose survivors of cardiac arrest; a systematic review with meta-analysis. Resuscitation. 2024. PMID: 39547562. doi:10.1016/j.resuscitation.2024.110431
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。